SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

Rhea-AI Summary

SeaStar Medical (Nasdaq: ICU) announced that CEO Eric Schlorff will present at NobleCon21 on Wednesday, December 3, 2025 at 4:00 PM ET at Florida Atlantic University in Boca Raton, Florida.

Investors and guests may register using code ICUNOBLECON. A replay will be posted on the company website on Thursday, December 4, 2025 after 4:00 PM ET and will remain available for 30 days following posting.

DENVER, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, Florida on Wednesday, December 3^rd at 4:00 pm Eastern Standard Time.

Interested investors and guests of SeaStar Medical are welcome to attend the conference. Please register here using the code ICUNOBLECON for the SeaStar Medical participation rate.

A replay of the presentation will be available on Thursday, December 4^th after 4:00 pm Eastern Standard Time on the Company's website and can be accessed here. The replay will be available for up to 30 days following its posting.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com

FAQ

When will SeaStar Medical (ICU) present at NobleCon21?

SeaStar Medical (ICU) will present on December 3, 2025 at 4:00 PM ET.

Who from SeaStar Medical will present at the NobleCon21 investor conference?

Chief Executive Officer Eric Schlorff will present for SeaStar Medical (ICU).

How can investors register to attend the SeaStar Medical (ICU) presentation at NobleCon21?

Register for the conference and use code ICUNOBLECON to access SeaStar Medical's participation.

When and where will the SeaStar Medical (ICU) presentation replay be available?

The replay will be posted on SeaStar Medical's website on December 4, 2025 after 4:00 PM ET and will be available for 30 days.

Where is NobleCon21 taking place for the SeaStar Medical (ICU) presentation?

NobleCon21 is at Florida Atlantic University Executive Education Complex in Boca Raton, Florida.

Is the SeaStar Medical (ICU) NobleCon21 presentation open to investors and guests?

Yes. Interested investors and guests of SeaStar Medical are welcome to attend and should register using the provided code.